Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Supramolecular salicylic acid (SSA) is a novel formulation that uses supramolecular technology to covalently bond salicylic acid with poloxamer 407, forming a more stable compound that easily dissolves in water. This formulation provides SSA with a stable structure and the ability to remain persistent on the skin, releasing active ingredients slowly and steadily, thereby enhancing the bioavailability of salicylic acid while reducing irritation and stinging sensations during treatment. SSA is a reversely thermo-reversible hydrogel with an adjustable solution-to-gel transition temperature in the range of 4–45°C. It exhibits keratolytic, anti-inflammatory, bacteriostatic, and photoprotective properties, making it effective for various dermatological conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on supramolecular salicylic acid.